Ipsen gains exclusive global rights, outside of Greater China, for development, manufacturing and commercialization of SIM0613, a LRRC15-targeting antibody-drug conjugateSIM0613 is optimally designed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback